Profile data is unavailable for this security.
About the company
Blau Farmaceutica SA is a Brazil-based company engaged in the pharmaceuticals sector. The Company focuses on the development, production and commercialization of medicines, which aim at treatment in the areas of oncology, nephrology, hematology and infectology, among others. Its product lines includes biopharmaceuticals, biosimilars, oncological - injectable, oncological - oral, blood products, antiviral and antiretrovirals, uterine stimulators, anaesthetics, antithrombotics, thrombolytics, female health care, antibiotics, non-beta lactams, cephalosporin, chloramphenicol, acid pumper inhibitor and other hospital products. The Company operates in Brazil, Argentina, Colombia, Peru, Uruguay, Chile and the United States, having a pharmaceutical industrial complex composed of five industrial plants, dedicated to the production of biological, biotechnological and oncological medicines, antibiotics, injectable anesthetics and biotechnological inputs.
- Revenue in BRL (TTM)1.47bn
- Net income in BRL237.95m
- Incorporated1987
- Employees1.90k
- LocationBlau Farmaceutica SARodovia Raposo Tavares2833 Km 30,5, Barro BrancoCOTIA 06.705-030BrazilBRA
- Phone+55 1 146159400
- Fax+55 1 146159401
- Websitehttps://www.blau.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ouro Fino Saude Animal Participacoes SA | 954.50m | -33.72m | 1.16bn | 1.01k | -- | 1.65 | 329.65 | 1.21 | -0.6271 | -0.6271 | 17.75 | 13.03 | 0.7329 | 1.82 | 4.93 | -- | -2.59 | 5.93 | -3.17 | 7.48 | 46.45 | 49.30 | -3.53 | 7.80 | 2.55 | 59.00 | 0.3749 | 16.83 | -9.40 | 9.87 | -138.25 | -- | -0.2692 | 14.07 |
| Biomm SA | 122.47m | -80.29m | 1.91bn | -- | -- | 5.93 | -- | 15.63 | -0.9128 | -0.9128 | 1.36 | 2.55 | 0.267 | 2.27 | 3.25 | -- | -17.50 | -19.78 | -20.82 | -24.35 | 20.27 | 20.27 | -65.56 | -95.65 | 3.33 | -17.42 | 0.3235 | -- | 12.62 | 137.44 | 12.34 | -- | 40.29 | -- |
| Blau Farmaceutica SA | 1.47bn | 237.95m | 1.92bn | 1.90k | 8.05 | 0.9423 | 6.86 | 1.30 | 1.33 | 1.33 | 8.24 | 11.37 | 0.5203 | 1.56 | 3.66 | 775,848.90 | 8.32 | 16.01 | 9.60 | 19.59 | 34.09 | 44.57 | 15.98 | 21.99 | 2.33 | -- | 0.2311 | 16.61 | -2.44 | 11.91 | -31.14 | 15.18 | 38.96 | -- |
| Genomma Lab Internacional SAB de CV | 5.08bn | 338.52m | 5.22bn | 1.59k | 14.52 | 1.61 | 12.58 | 1.03 | 1.14 | 1.14 | 17.28 | 10.34 | 0.764 | 2.90 | 3.66 | 10,095,660.00 | 5.09 | 5.79 | 8.21 | 8.64 | 62.23 | 61.70 | 6.67 | 7.88 | 1.32 | 2.55 | 0.3945 | 16.85 | -2.10 | 6.90 | -21.90 | -0.4465 | -26.37 | -- |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 09 May 2024 | 1.76m | 0.98% |
| �rtica Gest�o de Recursos Ltda.as of 30 Apr 2023 | 897.70k | 0.50% |
| Ventor Investimentos Ltda.as of 31 Jan 2024 | 571.10k | 0.32% |
| BTG Pactual WM Gest�o de Recursos Ltda.as of 31 Jan 2024 | 514.00k | 0.29% |
| Mellon Investments Corp.as of 09 May 2024 | 410.78k | 0.23% |
| BlackRock Brasil Gestora de Investimentos Ltda.as of 09 May 2024 | 399.75k | 0.22% |
| Vokin Administra��o de Recursos LTDAas of 31 Jan 2024 | 322.60k | 0.18% |
| Hix Investimentos Ltda.as of 31 Jan 2024 | 258.60k | 0.14% |
| Athena Capital Gest�o de Recursos Ltda.as of 30 Apr 2023 | 238.70k | 0.13% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 199.28k | 0.11% |
